Skip Navigation


Hum. Reprod. Advance Access originally published online on April 2, 2008
Human Reproduction 2008 23(6):1359-1365; doi:10.1093/humrep/den108
This Article
Right arrow Full Text
Right arrow Full Text (PDF )
Right arrow All Versions of this Article:
23/6/1359    most recent
den108v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Gnoth, C.
Right arrow Articles by Godehardt, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gnoth, C.
Right arrow Articles by Godehardt, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Relevance of anti-Mullerian hormone measurement in a routine IVF program

C. Gnoth1,2,5, A.N. Schuring3, K. Friol1, J. Tigges1, P. Mallmann2 and E. Godehardt4

1 Center for Family Planning, Gynecological Endocrinology and Reproductive Medicine, Rheydter Strasse 143, 41515 Grevenbroich, Germany 2 Department of Obstetrics and Gynecology, University of Cologne, Cologne, Germany 3 Department of Obstetrics and Gynecology, University of Muenster, Muenster, Germany 4 Biometric Research Group, Clinic for Thoracic and Cardiovascular Surgery, Heinrich-Heine University of Duesseldorf, Duesseldorf, Germany

5 Correspondence address. Tel: +49-2181-491513; Fax: +49 2181-491534; E-mail: dr.christian.gnoth{at}rmz-nrw.de

BACKGROUND: Diminished ovarian reserve has become a major cause of infertility. Anti-Mullerian hormone (AMH) seems to be a promising candidate to assess ovarian reserve and predict the response to controlled ovarian hyperstimulation (COH). This prospective study was conducted to evaluate the relevance of AMH in a routine IVF program.

METHODS: Three hundred and sixteen patients were prospectively enrolled to enter their first IVF/ICSI-cycle. Age, FSH-, inhibin B- and AMH-levels and their predictive values for ovarian response and clinical pregnancy rate were compared by discriminant analyses.

RESULTS: A total of 132 oocyte retrievals were performed. A calculated cut-off level ≤1.26 ng/ml AMH alone detected poor responders (≤4 oocytes) with a sensitivity of 97%, and there was a 98% correct prediction of normal response in COH if levels were above this threshold. With levels <0.5 ng/ml, a correct prediction of very poor response (≤2 oocytes) was possible in 88% of cases. Levels of AMH ≥0.5 ng/ml were not significantly correlated with clinical pregnancy rates.

CONCLUSIONS: AMH is a predictor of ovarian response and suitable for screening. Levels ≤1.26 ng/ml are highly predictive of reduced ovarian reserve and should be confirmed by a second line antral follicle count. Measurement of AMH supports clinical decisions, but alone it is not a suitable predictor of IVF success.

Submitted on August 21, 2007; resubmitted on March 3, 2008; accepted on March 12, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.